An March 4, 2026, Die US-amerikanische Food and Drug Administration (FDA) issued abschließende Leitlinien outlining the general principles for planning, designing, analyzing, and reporting non-interventional studies that use real-world data (RWD) to assess the safety of medicines. The guidance applies to drugs, vaccines, and biological products and establishes regulatory expectations for postmarketing safety studies conducted by pharmaceutical and biologics sponsors.
The document standardizes how non-interventional studies should be conducted when using real-world data sources such as electronic health records and insurance claims, providing clarity on study design, methodology, and reporting practices. It replaces earlier draft guidance and withdraws the FDA’s May 2013 guidance on pharmacoepidemiologic safety studies using electronic healthcare datasets.
Details zum Update
The final guidance defines non-interventional studies as research approaches that observe outcomes without assigning specific treatments or interventions. These studies rely on real-world data collected during routine healthcare delivery.
The FDA recommends that sponsors begin by clearly formulating research questions and identifying appropriate real-world data sources that can support reliable safety assessments. The guidance also emphasizes the need to define study variables and endpoints precisely, ensuring that datasets and analytical approaches are suitable for the intended safety evaluation.
In addition, the document highlights the importance of addressing bias and confounding factors during study design and analysis. Sponsors are expected to incorporate methods to identify, assess, and mitigate potential sources of bias that may affect safety conclusions.
The FDA further outlines expectations for transparent study documentation and comprehensive reporting, including detailed descriptions of methodologies, data sources, and analytical approaches used in the study.
Datum des Inkrafttretens
Der FDA’s final guidance on non-interventional studies using real-world data wurde effective on March 4, 2026.
Warum es wichtig ist
Dieses Update bietet regulatory clarity for the use of real-world data in postmarketing safety surveillance. By standardizing study design, bias management, and reporting practices, the guidance supports more consistent, reliable, and transparent safety evaluations while enabling efficient use of existing healthcare data sources.
Für wen ist das relevant?
The guidance is relevant for teams involved in postmarketing surveillance and safety evaluation, einschließlichRegulatory Affairs, Quality Assurance, Patient Safety, Legal and Compliance, Commercial or Marketing, and R&D functions within pharmaceutical and biologics organizations.
Nächste Schritte
Organizations conducting non-interventional safety studies using real-world data should review current study protocols and methodologies to ensure alignment with the FDA’s updated expectations. Stakeholders should also evaluate documentation practices and reporting processes across relevant departments to confirm that study designs, data selection methods, and analytical approaches meet the new standards.
As regulatory agencies increasingly formalize expectations around real-world data and postmarket safety monitoring, organizations may benefit from tools that help track evolving regulatory guidance and operationalize compliance across global markets.
RegASK ist eine führende agentenbasierte KI-Plattform für regulatorische Intelligenz und Workflow-Orchestrierung, die globale Organisationen in stark regulierten Sektoren, darunter Konsumgüter und Biowissenschaften, in die Lage versetzt, proaktiv durch komplexe regulatorische Landschaften zu navigieren. Durch die Kombination von fortschrittlicher Agentic-KI mit Expertenwissen, RegASK liefert zeitnahe, vorausschauende und umsetzbare Erkenntnisse sowie eine durchgängige Automatisierung, optimiert Compliance-Prozesse, mindert Risiken und beschleunigt den Marktzugang in mehr als 160 Ländern. Mehr erfahren oder Jetzt Demo buchen.
FAQs
What is the FDA’s 2026 guidance on non-interventional studies using real-world data?
The guidance outlines general principles for planning, designing, analyzing, and reporting non-interventional studies that use real-world data to evaluate the safety of drugs, vaccines, and biological products in postmarketing settings.
What types of data are considered real-world data in this guidance?
The FDA identifies data sources such as electronic health records and insurance claims as examples of real-world data that can be used in non-interventional safety studies.
Does this guidance replace previous FDA recommendations?
Yes. The final guidance withdraws the FDA’s May 2013 guidance on pharmacoepidemiologic safety studies using electronic healthcare datasets and replaces earlier draft recommendations.
Wie kann RegASK Unternehmen dabei helfen, regulatorische Aktualisierungen im Zusammenhang mit Säuglingsnahrung zu überwachen?
RegASK helps organizations track evolving regulatory guidance, interpret compliance requirements, and streamline regulatory workflows, enabling regulatory, safety, and compliance teams to respond more efficiently to updates such as the FDA’s new guidance on real-world data studies.
Abonnieren Sie die neuesten regulatorischen Nachrichten
Kuratierte Newsletter
Relevante Brancheninfos
Zugriff auf Expertenwissen
